Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Benign Prostatic Hyperplasia Therapeutics industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Abbott Laboratories
Sanofi
Merck & Co
Pfizer
Teva Pharmaceutical Industries Limited
Astellas Pharma
Allergan plc
GlaxoSmithKline plc
Boehringer Ingelheim Pharma GmbH & Co KG
By Type:
Others
Alpha blocker
Phosphodiesterase-5 inhibitor
5-Alpha reductase inhibitor
By Application:
Combination drug therapy
Mono drug therapy
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Benign Prostatic Hyperplasia Therapeutics Market Overview 2018-2029
-
1.1 China Benign Prostatic Hyperplasia Therapeutics Industry Development Overview
-
1.2 China Benign Prostatic Hyperplasia Therapeutics Industry Development History
-
1.3 China Benign Prostatic Hyperplasia Therapeutics Industry Market Size (2018-2029)
-
1.4 China Benign Prostatic Hyperplasia Therapeutics Market Analysis by Type from Production Side
-
1.4.1 China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of Others (2018-2029)
-
1.4.2 China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of Alpha blocker (2018-2029)
-
1.4.3 China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of Phosphodiesterase-5 inhibitor (2018-2029)
-
1.4.4 China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of 5-Alpha reductase inhibitor (2018-2029)
-
1.5 China Benign Prostatic Hyperplasia Therapeutics Market Analysis by Application from Consumption End
-
1.5.1 China Benign Prostatic Hyperplasia Therapeutics Sales Volume, Sales Value and Growth Rate of Combination drug therapy (2018-2029)
-
1.5.2 China Benign Prostatic Hyperplasia Therapeutics Sales Volume, Sales Value and Growth Rate of Mono drug therapy (2018-2029)
-
1.6 China Benign Prostatic Hyperplasia Therapeutics Market Analysis by Region
-
1.6.1 North China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
Chapter 2 China Benign Prostatic Hyperplasia Therapeutics Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Benign Prostatic Hyperplasia Therapeutics Market Status and Competition at home and abroad in 2023
-
2.2.2 China Benign Prostatic Hyperplasia Therapeutics Market Status and Competition Analysis in 2023
-
2.2.3 China Benign Prostatic Hyperplasia Therapeutics Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Benign Prostatic Hyperplasia Therapeutics Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Benign Prostatic Hyperplasia Therapeutics Industry Development
Chapter 3 Benign Prostatic Hyperplasia TherapeuticsIndustry Chain Analysis
-
3.1 Benign Prostatic Hyperplasia Therapeutics Industry Chain
-
3.2 Benign Prostatic Hyperplasia Therapeutics Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Benign Prostatic Hyperplasia Therapeutics Market
-
3.3 Benign Prostatic Hyperplasia Therapeutics Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Benign Prostatic Hyperplasia Therapeutics Market
Chapter 4 China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
4.1 China Benign Prostatic Hyperplasia Therapeutics Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Benign Prostatic Hyperplasia Therapeutics Total Production Volume and Growth Rate from Production Side
-
4.5 China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate, by Type
-
4.5.1 China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of Others
-
4.5.2 China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of Alpha blocker
-
4.5.3 China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of Phosphodiesterase-5 inhibitor
-
4.5.4 China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of 5-Alpha reductase inhibitor
Chapter 5 China Benign Prostatic Hyperplasia Therapeutics Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Benign Prostatic Hyperplasia Therapeutics Total Market Size and Growth Rate from Consumption End
-
5.5 China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate, by Application
-
5.5.1 China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate of Combination drug therapy
-
5.5.2 China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate of Mono drug therapy
Chapter 6 China Benign Prostatic Hyperplasia Therapeutics Market, by Region
-
6.1 China Benign Prostatic Hyperplasia Therapeutics Production Volume and Production Value, by Region
-
6.2 China Benign Prostatic Hyperplasia Therapeutics Sales Volume and Sales Value, by Region
Chapter 7 North China Benign Prostatic Hyperplasia Therapeutics Market Analysis
-
7.1 North China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
7.2 North China Benign Prostatic Hyperplasia Therapeutics Market, by Application
Chapter 8 Central China Benign Prostatic Hyperplasia Therapeutics Market Analysis
-
8.1 Central China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
8.2 Central China Benign Prostatic Hyperplasia Therapeutics Market, by Application
Chapter 9 South China Benign Prostatic Hyperplasia Therapeutics Market Analysis
-
9.1 South China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
9.2 South China Benign Prostatic Hyperplasia Therapeutics Market, by Application
Chapter 10 East China Benign Prostatic Hyperplasia Therapeutics Market Analysis
-
10.1 East China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
10.2 East China Benign Prostatic Hyperplasia Therapeutics Market, by Application
Chapter 11 Northeast China Benign Prostatic Hyperplasia Therapeutics Market Analysis
-
11.1 Northeast China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
11.2 Northeast China Benign Prostatic Hyperplasia Therapeutics Market, by Application
Chapter 12 Southwest China Benign Prostatic Hyperplasia Therapeutics Market Analysis
-
12.1 Southwest China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
12.2 Southwest China Benign Prostatic Hyperplasia Therapeutics Market, by Application
Chapter 13 Northwest China Benign Prostatic Hyperplasia Therapeutics Market Analysis
-
13.1 Northwest China Benign Prostatic Hyperplasia Therapeutics Market, by Type
-
13.2 Northwest China Benign Prostatic Hyperplasia Therapeutics Market, by Application
Chapter 14 Company Profiles
-
14.1 Abbott Laboratories
-
14.1.1 Abbott Laboratories Company Profile
-
14.1.2 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Sanofi
-
14.2.1 Sanofi Company Profile
-
14.2.2 Sanofi Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Merck & Co
-
14.3.1 Merck & Co Company Profile
-
14.3.2 Merck & Co Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Pfizer
-
14.4.1 Pfizer Company Profile
-
14.4.2 Pfizer Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Teva Pharmaceutical Industries Limited
-
14.5.1 Teva Pharmaceutical Industries Limited Company Profile
-
14.5.2 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 Astellas Pharma
-
14.6.1 Astellas Pharma Company Profile
-
14.6.2 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Allergan plc
-
14.7.1 Allergan plc Company Profile
-
14.7.2 Allergan plc Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 GlaxoSmithKline plc
-
14.8.1 GlaxoSmithKline plc Company Profile
-
14.8.2 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Boehringer Ingelheim Pharma GmbH & Co KG
-
14.9.1 Boehringer Ingelheim Pharma GmbH & Co KG Company Profile
-
14.9.2 Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Market Performance
-
14.9.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Benign Prostatic Hyperplasia Therapeutics Industry Research Conclusions
-
15.2 Benign Prostatic Hyperplasia Therapeutics Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Benign Prostatic Hyperplasia Therapeutics Industry Market Size (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of Others (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of Alpha blocker (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of Phosphodiesterase-5 inhibitor (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume, Production Value and Growth Rate of 5-Alpha reductase inhibitor (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Sales Volume, Sales Value and Growth Rate of Combination drug therapy (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Sales Volume, Sales Value and Growth Rate of Mono drug therapy (2018-2029)
-
Figure North China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
Figure Central China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
Figure South China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
Figure East China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate from 2018-2029
-
Figure Benign Prostatic Hyperplasia Therapeutics Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Benign Prostatic Hyperplasia Therapeutics Market Share by Type in 2018
-
Figure China Benign Prostatic Hyperplasia Therapeutics Market Share by Type in 2023
-
Figure China Benign Prostatic Hyperplasia Therapeutics Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of Others (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of Alpha blocker (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of Phosphodiesterase-5 inhibitor (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume and Growth Rate of 5-Alpha reductase inhibitor (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Market Share by Application in 2018
-
Figure China Benign Prostatic Hyperplasia Therapeutics Market Share by Application in 2023
-
Figure China Benign Prostatic Hyperplasia Therapeutics Total Market Size and Growth Rate from Consumption End
-
Figure China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate of Combination drug therapy (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Market Size and Growth Rate of Mono drug therapy (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Production Volume by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Production Value by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Production Value Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Production Value Share by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Sales Value by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Therapeutics Sales Value Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Sales Value Share by Region (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Therapeutics Production Volume by Type (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Figure North China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Application (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Figure North China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Therapeutics Production Volume by Type (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Figure Central China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Application (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Figure Central China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Therapeutics Production Volume by Type (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Figure South China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Application (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Figure South China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Therapeutics Production Volume by Type (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Figure East China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Application (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Figure East China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Therapeutics Production Volume by Type (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Figure Northeast China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Application (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Therapeutics Production Volume by Type (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Figure Southwest China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Application (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Therapeutics Production Volume by Type (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Figure Northwest China Benign Prostatic Hyperplasia Therapeutics Production Volume Share by Type (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Therapeutics Sales Volume by Application (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Benign Prostatic Hyperplasia Therapeutics Sales Volume Share by Application (2018-2023)
-
Table Abbott Laboratories Company Profile
-
Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table Sanofi Company Profile
-
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table Merck & Co Company Profile
-
Table Merck & Co Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table Pfizer Company Profile
-
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table Teva Pharmaceutical Industries Limited Company Profile
-
Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table Astellas Pharma Company Profile
-
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table Allergan plc Company Profile
-
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table GlaxoSmithKline plc Company Profile
-
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Company Profile
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Revenue, Price and Gross (2018-2023)
-
